Cargando…

Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: A Phase III, open-label, multi-center study

Booster doses of meningococcal conjugate vaccines induce long-term protection against invasive meningococcal disease. We evaluated the immunogenicity and safety of a booster dose of MenACYW-TT in pre-school children who were primed 3 years earlier with MenACYW-TT or MCV4-TT (Nimenrix®). In this Phas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Piazza, Franco M., Virta, Miia, Paassilta, Marita, Ukkonen, Benita, Ahonen, Anitta, Esteves-Jaramillo, Alejandra, Forsten, Aino, Seppa, Ilkka, Ding, Jian, Neveu, David, Jordanov, Emilia, Dhingra, Mandeep S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Meningococcal – Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920225/ https://www.ncbi.nlm.nih.gov/pubmed/34085900 http://dx.doi.org/10.1080/21645515.2021.1902701

Ejemplares similares

Safety and immunogenicity of quadrivalent meningococcal polysaccharide vaccine (MPV ACYW135) compared with quadrivalent meningococcal conjugate vaccine (Menactra®) in Malian children
por: Sow, Samba O., et al.
Publicado: (2023)

Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-naïve toddlers: A randomised, controlled trial
por: Knuf, Markus, et al.
Publicado: (2022)

Pandemic’s influence on parents’ attitudes and behaviors toward meningococcal vaccination
por: Tan, Litjen (L.J), et al.
Publicado: (2023)

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) vs. a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine in meningococcal vaccine-naïve and meningococcal C conjugate vaccine-primed toddlers: a phase III randomised study
por: van der Vliet, D., et al.
Publicado: (2021)

Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster to adults aged ≥59 years: A phase III randomized study
por: Robertson, Corwin A., et al.
Publicado: (2023)

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized study
por: Vesikari, Timo, et al.
Publicado: (2020)

Serum bactericidal activity against circulating and reference strains of meningococcal serogroup B in the United States: A review of the strain coverage of meningococcal serogroup B (MenB) vaccines in adolescents and young adults
por: Presa, Jessica, et al.
Publicado: (2023)

Meningococcal disease within the Gulf Cooperation Council Countries
por: Al Awaidy, Salah, et al.
Publicado: (2023)

Meningococcal serogroup B vaccination series initiation in the United States: A real-world claims data analysis
por: Packnett, Elizabeth R., et al.
Publicado: (2023)

Safety and immunogenicity of co-administered meningococcal serogroup B (4CMenB) vaccine: A literature review
por: Abitbol, Véronique, et al.
Publicado: (2023)

Review of the epidemiology, diagnosis and management of invasive meningococcal disease in Vietnam
por: The Nguyen, Phung Nguyen, et al.
Publicado: (2023)

Changing patterns of invasive meningococcal disease and future immunization strategies
por: Taha, Muhamed-Kheir, et al.
Publicado: (2023)

Meningococcal burden of disease in Argentina: 10 years epidemiologic review
por: Neyro, Silvina, et al.
Publicado: (2023)

Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age
por: Marshall, Gary S., et al.
Publicado: (2022)

Meningococcal carriage in the African meningitis belt
Publicado: (2013)

Preventing invasive meningococcal disease in early infancy
por: Presa, Jessica, et al.
Publicado: (2022)

Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine
por: Vesikari, Timo, et al.
Publicado: (2015)

03. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered as a Booster Dose in Adults and Adolescents Vaccinated Against Meningococcal Disease 3 - 6 Years Earlier
por: Peterson, James, et al.
Publicado: (2021)

Immunogenicity and safety of different schedules of the meningococcal ABCWY vaccine, with assessment of long-term antibody persistence and booster responses – results from two phase 2b randomized trials in adolescents
por: Vesikari, Timo, et al.
Publicado: (2021)

Postmarketing surveillance of adverse events following meningococcal B vaccination: data from Apulia Region, 2014–19
por: Stefanizzi, Pasquale, et al.
Publicado: (2021)

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine administered concomitantly with other paediatric vaccines in toddlers: a phase III randomised study
por: Dhingra, M. S., et al.
Publicado: (2021)

2724. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Healthy Meningococcal Vaccine-Naïve Children (2–9 Years)
por: Simon, Michael W, et al.
Publicado: (2019)

2462. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Individuals 56 Years of Age and Older
por: Jeanfreau, Robert, et al.
Publicado: (2018)

2723. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Adolescents 10–17 Years of Age
por: Peterson, James, et al.
Publicado: (2019)

2719. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Adults 18–55 Years of Age
por: Peterson, James, et al.
Publicado: (2019)

Economic burden of meningococcal disease in children and adolescents in Tijuana, Mexico
por: Chacon-Cruz, Enrique, et al.
Publicado: (2022)

Invasive meningococcal disease in Malaysia, Philippines, Thailand, and Vietnam: An Asia-Pacific expert group perspective on current epidemiology and vaccination policies
por: Thisyakorn, Usa, et al.
Publicado: (2022)

Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Meningococcal-Naïve Children 2–9 Years of Age: A Phase III, Randomized Study
por: Baccarini, Carmen I., et al.
Publicado: (2020)

Proceedings of the Expert Consensus Group meeting on meningococcal serogroup B disease burden and prevention in India
por: Dubey, Anand P., et al.
Publicado: (2022)

Care pathways in invasive meningococcal disease: a retrospective analysis of the French national public health insurance database
por: Weil-Olivier, Catherine, et al.
Publicado: (2022)

Persistence of antibodies in laboratory staff immunized with quadrivalent meningococcal polysaccharide vaccine
por: Elias, Johannes, et al.
Publicado: (2013)

Prevalence of Neisseria meningitidis serogroups in invasive meningococcal disease in China, 2010 - 2020: a systematic review and meta-analysis
por: Xu, Juan, et al.
Publicado: (2022)

04. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Meningococcal Vaccine-Naive Participants Across a Broad Age Range (2-55 Years) in Japan
por: Matsuoka, Osamu, et al.
Publicado: (2021)

Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study
por: Zambrano, Betzana, et al.
Publicado: (2023)

Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine
por: Watle, Sara Viksmoen, et al.
Publicado: (2021)

2725. Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Adolescents and Adults
por: Hedrick, James, et al.
Publicado: (2019)

1967. Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) When Co-administered with Other Vaccines in Healthy Adolescents
por: Hedrick, James, et al.
Publicado: (2018)

Meningococcal B Vaccination (4CMenB) in Infants and Toddlers
por: Esposito, Susanna, et al.
Publicado: (2015)

Control of meningococcal meningitis with meningococcal vaccines.
por: Artenstein, M. S.
Publicado: (1975)

2461. Safety of Quadrivalent Meningococcal Polysaccharide Diphtheria Toxoid-Conjugate Vaccine in Adolescents
por: Myers, Tanya, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vo578f3obhv6noe3ir9vthm0ip